Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline maintenance after ketamine response in depressive disorder
NL-OMON40601Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of minocycline and ketamine in major depressive disorder (MDD) and Bipolar II disorder (BP-II) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Relapse-free survival proportion at Day 54 among ketamine responders. Started Aug 2013; status: active, not recruiting.
02
Drugs
minocyclineketamine
03
Conditions
major depressive disorder (MDD)Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on NL-OMON40601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40601.